Home / Aduhelm (Drug) / Alzheimer's Disease / Clinical Trials / Drugs (Pharmaceuticals) / Labeling and Labels (Product) / In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

The Guardian Express Friday, July 09, 2021 Aduhelm (Drug), Alzheimer's Disease, Clinical Trials, Drugs (Pharmaceuticals), Labeling and Labels (Product)

https://ift.tt/3wpL7KI
The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms. By BY REBECCA ROBBINS AND PAM BELLUCK from NYT https://ift.tt/3wpL7KI

No comments

Subscribe to: Post Comments ( Atom )